H. Lee Moffitt Cancer Center & Research Institute Patent applications |
Patent application number | Title | Published |
20140326891 | METHOD AND APPARATUS FOR DETECTION OF RADIOACTIVE ISOTOPES - A method and apparatus for detecting an isotope. Embodiments can detect radioactive isotopes. Embodiments can utilize a detector that incorporates at least two sub-detectors. Each sub-detector can receive energy from an isotope and create a signal corresponding to the received energy. Each sub-detector can incorporate a detector element, such as a detector element incorporating one or more diodes, a detector element incorporating a crystal, a detector element incorporating a solid-state device, or a detector element incorporating a scintillator. The sub-detectors can be configured such that for each isotope to be detected at least two of the sub-detectors produce different output signals, or readings. In an embodiment, each sub-detector is configured such that when there are at least two sub-detectors exposed to the isotope each of the corresponding readings from the sub-detectors is different from each of the other readings. | 11-06-2014 |
20130299709 | METHOD AND APPARATUS FOR DETECTION OF RADIOACTIVE ISOTOPES - A method and apparatus for detecting an isotope. embodiments can detect radioactive isotopes. Embodiments can utilize a detector that incorporates at least two sub-detectors. Each sub-detector can receive energy from an isotope and create a signal corresponding to the received energy. Each sub-detector can incorporate a detector element, such as a detector element incorporating one or more diodes, a detector element incorporating a crystal, a detector element incorporating a solid-state device, or a detector element incorporating a scintillator. The sub-detectors can be configured such that for each isotope to be detected at least two of the sub-detectors produce different output signals, or readings. In an embodiment, each sub-detector is configured such that when there are at least two sub-detectors exposed to the isotope each of the corresponding readings from the sub-detectors are different from each of the other readings. | 11-14-2013 |
20130194266 | METHOD AND APPARATUS FOR USE OF FUNCTION-FUNCTION SURFACES AND HIGHER-ORDER STRUCTURES AS A TOOL - Embodiments of the invention relate to a method and apparatus for displaying information. In a specific embodiment, at least two pluralities of voxel values for a corresponding at least two functions with respect to at least a portion of a subject can be obtained. The at least a portion of the subject can have a plurality of local volume elements, where the at least two pluralities of voxel values for the corresponding at least two functions each correspond to the plurality of local volume elements. In this way, there is a voxel value for each function for each local volume element of the portion of the subject. Each of the at least two pluralities of voxel values represents the value of the corresponding function of the at least two functions for the corresponding plurality of local volume elements. A representation is created where the value of one of the at least two functions is on a first axis and a count of voxels is on a second axis. The count of voxels on the second axis is at least a portion of the count of voxels having the value of the one of the at least two functions on the first axis. In another embodiment, the value of the other one of the at least two functional mechanisms can be on a third axis. The count of voxels on the second axis can then be the count of voxels having the value of the one of the at least two functional mechanisms on the first axis and having the value of the other one of the at least two functional mechanisms on the third axis. | 08-01-2013 |
20130059015 | Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response - Disclosed are identified and successfully targeted microRNAs (miRNAs) associated with human cancer cell line response to a range of anti-cancer agents. The strategy of integrating in vitro miRNA expression and drug sensitivity data not only aid in the characterization of determinants of cytotoxic response, but also in the identification of novel therapeutic targets. | 03-07-2013 |
20110201609 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS - The subject invention concerns compounds having activity as inhibitors of proteasomes and methods of using the subject compounds. In one embodiment, a compound of the invention has the chemical structure shown in formula I: | 08-18-2011 |
20110201576 | Small molecule inhibitors of stat3 with anti-tumor activity - The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents. | 08-18-2011 |
20090069420 | Small molecule inhibitors of STAT3 with anti-tumor activity - The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents. | 03-12-2009 |